No evidence exists as to whether body mass index (BMI) impairs clinical outcomes from ALK inhibitors (ALKi) in patients with ALK-rearranged non-small cell lung cancer (NSCLC). Retrospective data of patients affected by metastatic ALK-rearranged NSCLC treated with ALKi were collected. We divided patients into “low- BMI” (≤25 kg/m2) and “high- BMI” (>25 kg/m2) categories and correlated them with overall survival (OS) and progression-free survival (PFS). We included 40 patients treated with ALKi. We observed a 3-year OS of 81.5% in high-BMI vs. 49.6% in low-BMI categories (p = 0.049); the 3-year first-line PFS was superior in high-BMI vs. low-BMI patients (47% vs. 19%, p = 0.019). As expected, patients treated with Alectinib had a 55.6% 3-year PFS vs. 7.1% for others treated with ALKi (p = 0.025). High-BMI was associated with a 100% 3-year PFS rate vs. 25.4% in low-BMI Alectinib patients (p = 0.03). BMI was independently correlated with first-line PFS and OS at multivariate analysis with PS (HR 0.39, CI 95% 0.16–0.96, p = 0.042; HR 0.18, CI 95% 0.05–0.61, p = 0.006). High-BMI was associated with higher efficacy in ALK-rearranged patients. These results are particularly exciting for Alectinib and could be correlated to mechanisms that should be investigated in subsequent prospective studies.

Evaluation of efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients—A retrospective observational study / Siringo, Marco; Gentile, Gabriella; Caponnetto, Salvatore; Sperduti, Isabella; Santini, Daniele; Cortesi, Enrico; Gelibter, ALAIN JONATHAN. - In: CANCERS. - ISSN 2072-6694. - 15:13(2023). [10.3390/cancers15133422]

Evaluation of efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients—A retrospective observational study

Marco Siringo
Primo
;
Gabriella Gentile
Secondo
;
Salvatore Caponnetto;Daniele Santini;Enrico Cortesi
Penultimo
;
Alain Jonathan Gelibter
Ultimo
2023

Abstract

No evidence exists as to whether body mass index (BMI) impairs clinical outcomes from ALK inhibitors (ALKi) in patients with ALK-rearranged non-small cell lung cancer (NSCLC). Retrospective data of patients affected by metastatic ALK-rearranged NSCLC treated with ALKi were collected. We divided patients into “low- BMI” (≤25 kg/m2) and “high- BMI” (>25 kg/m2) categories and correlated them with overall survival (OS) and progression-free survival (PFS). We included 40 patients treated with ALKi. We observed a 3-year OS of 81.5% in high-BMI vs. 49.6% in low-BMI categories (p = 0.049); the 3-year first-line PFS was superior in high-BMI vs. low-BMI patients (47% vs. 19%, p = 0.019). As expected, patients treated with Alectinib had a 55.6% 3-year PFS vs. 7.1% for others treated with ALKi (p = 0.025). High-BMI was associated with a 100% 3-year PFS rate vs. 25.4% in low-BMI Alectinib patients (p = 0.03). BMI was independently correlated with first-line PFS and OS at multivariate analysis with PS (HR 0.39, CI 95% 0.16–0.96, p = 0.042; HR 0.18, CI 95% 0.05–0.61, p = 0.006). High-BMI was associated with higher efficacy in ALK-rearranged patients. These results are particularly exciting for Alectinib and could be correlated to mechanisms that should be investigated in subsequent prospective studies.
2023
ALK; alectinib; NSCLC; BMI; predictive biomarker
01 Pubblicazione su rivista::01a Articolo in rivista
Evaluation of efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients—A retrospective observational study / Siringo, Marco; Gentile, Gabriella; Caponnetto, Salvatore; Sperduti, Isabella; Santini, Daniele; Cortesi, Enrico; Gelibter, ALAIN JONATHAN. - In: CANCERS. - ISSN 2072-6694. - 15:13(2023). [10.3390/cancers15133422]
File allegati a questo prodotto
File Dimensione Formato  
Siringo_Evaluation of_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.85 MB
Formato Adobe PDF
1.85 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1684569
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact